Sandoz Doesn’t Need Biosimilars Purchases, Chief Tells Finanz
Novartis AG (NOVN)’s Sandoz unit doesn’t need acquisitions in the biosimilars business, Finanz und Wirtschaft reported, citing an interview with Jeff George, who heads the unit.
George said he expects a “shakeout” in the market as some smaller companies lack the technological abilities and commercial understanding needed to bring about sophisticated biosimilars, the newspaper reported.
To contact the reporter on this story: Elena Logutenkova in Zurich at firstname.lastname@example.org
To contact the editor responsible for this story: Frank Connelly at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.